UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
Commission
file number 001-41291
Meihua
International Medical Technologies Co., Ltd.
(Translation of registrant’s name into English)
88 Tongda Road, Touqiao Town
Guangling District, Yangzhou, 225000
People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Entry into the Leak-Out Agreement
As previously disclosed, on January 22, 2026,
each of the purchasers in the private placements that Meihua International Medical Technologies Co., Ltd. offered on October 8 and December
5, 2025 (collectively, the “Purchasers”) entered into a lock-up agreement (the “Lock-Up Agreement”) with the Company,
pursuant to which the Purchasers agreed not to offer, sell, or otherwise dispose of any securities of the Company (the “Securities”)
for a period of twelve (12) months following the applicable closing, subject to the terms and conditions set forth therein.
On January 29, 2026, the Company entered into
leak-out agreements with each Purchaser, pursuant to which the Company agrees to waive the lock-up provisions set forth in the Lock-Up
Agreement with respect to all of the Securities. In exchange, each Purchaser agreed to limit resales of the Securities during the lock-up
period to no more than 15% of the average daily trading volume over the prior ten trading days.
A form of the Leak-Out Agreement is furnished
hereto as Exhibit 99.1 and such document is incorporated herein by reference. The foregoing is only a brief description of the material
terms of the Leak-Out Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder
and is qualified in its entirety by reference to such exhibit.
Exhibits
| Exhibit No. |
|
Description |
| 99.1 |
|
Form of the Leak-Out Agreement |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| Meihua International Medical Technologies Co., Ltd. |
| |
|
| By: |
/s/ Leyi Lee |
|
| Name: |
Leyi Lee |
|
| Title: |
Chief Executive Officer |
|
| |
|
| Date: February 2, 2026 |
|
Exhibit 99.1
FORM OF LEAK-OUT AGREEMENT
[ ], 2026
Meihua International Medical Technologies Co.,
Ltd.
| Re: | Securities Purchase Agreement, dated as of [ ], 2025 (the “Agreement”) and Lock-up
Agreement dated January 22, 2026 (the “Lock-up Agreement”), between Meihua International Medical Technologies Co., Ltd., a
Cayman Islands company (the “Company”) and the purchasers signatory thereto (each a “Purchaser”,
and collectively, the “Purchasers”) |
Ladies and Gentlemen:
The Company hereby
waives the Lock-Up provision for all of the Securities set forth in the Lock-up Agreement, provided that the undersigned irrevocably
agrees with the Company that, during the period (“Leak-out Period”) commencing on the date (the “Leak-Out
Commencement Date”) that the Securities are registered for resale pursuant to an effective registration statement or may be
sold pursuant to Rule 144 and ending on the expiration Date of the Restriction Period, shall not sell, on any Trading Day (any such date,
a “Date of Determination”), a number of Securities representing more than 15% of the average daily trading volume during
the ten (10) consecutive Trading Day leading up to any Date of Determination while the Ordinary Share is traded on any of the following
markets or exchanges on which the Ordinary Shares are listed or quoted for trading on the date in question: the Nasdaq Capital Market,
the Nasdaq Global Market, the Nasdaq Global Select Market, the NYSE American, or the New York Stock Exchange (or any successors to any
of the foregoing).
“Trading Day”
means a day on which the Ordinary Shares are traded on any of the following markets or exchanges on which the Ordinary Shares are listed
or quoted for trading on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
NYSE American, or the New York Stock Exchange (or any successors to any of the foregoing).
This Leak-out Agreement may
not be amended or otherwise modified in any respect without the written consent of each of the Company, the Purchasers and the undersigned.
This Leak-out Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to the principles
of conflict of laws. The undersigned hereby irrevocably submits to the exclusive jurisdiction of the United States District Court sitting
in the Southern District of New York and the courts of the State of New York located in Manhattan, for the purposes of any suit, action
or proceeding arising out of or relating to this Leak-out Agreement, and hereby waives, and agrees not to assert in any such suit, action
or proceeding, any claim that (i) it is not personally subject to the jurisdiction of such court, (ii) the suit, action or proceeding
is brought in an inconvenient forum, or (iii) the venue of the suit, action or proceeding is improper. The undersigned hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by receiving a copy thereof
sent to the Company at the address in effect for notices to it under the Agreement and agrees that such service shall constitute good
and sufficient service of process and notice thereof. The undersigned hereby waives any right to a trial by jury. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. The undersigned agrees and understands
that this Leak-out Agreement does not intend to create any relationship between the undersigned and any Purchaser and that no Purchaser
is entitled to cast any votes on the matters herein contemplated and that no issuance or sale of the Securities is created or intended
by virtue of this Leak-out Agreement.
This Leak-out Agreement shall
be binding on successors and assigns of the undersigned with respect to the Securities and any such successor or assign shall enter into
a similar agreement for the benefit of the Company. This Leak-out Agreement is intended for the benefit of the parties hereto and their
respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.
Defined terms not otherwise
defined in this Leak-out Agreement shall have the meanings set forth in the Agreement and the Lock-up Agreement.
*** SIGNATURE PAGE FOLLOWS***
This Leak-out Agreement may
be executed in two or more counterparts, all of which when taken together may be considered one and the same agreement.
| |
|
| Signature |
|
| |
|
| |
|
| Print Name |
|
| |
|
| |
|
| Position in Company, if any |
|
| |
|
| Address for Notice: |
|
By signing below, the Company
agrees to enforce the restrictions on transfer set forth in this Leak-out Agreement.
Meihua International Medical Technologies Co.,
Ltd.
| By: |
|
|
| Name: |
LEYI LEE |
|
| Title: |
CHIEF EXECUTIVE OFFICER |
|
[Signature Page to Leak-out
Agreement]
